Markers of endothelial damage in organ dysfunction and sepsis

Critical Care Medicine

Volumn 30, Issue 5 SUPPL., 2002, Pages

  Reinhart, Konrad ^a   Bayer, Ole ^a   Brunkhorst, Frank ^a   Meisner, Michael ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Coagulation parameters; Endothelium; Interleukin 6; Organ dysfunction; Procalcitonin; Sepsis

Indexed keywords

CELL ADHESION MOLECULE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; PROCALCITONIN; THROMBOMODULIN; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

BLOOD CLOTTING; CONFERENCE PAPER; DISEASE COURSE; DISEASE SEVERITY; ENDOTHELIUM INJURY; HUMAN; INFLAMMATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0036255482     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200205001-00021     Document Type: Conference Paper

References (115)

1. The endothelium in sepsis: Source of and a target for inflammation
2. Coagulation system and platelets are fully activated in uncomplicated sepsis
3. Efficacy and safety of recombinant human activated protein C for severe sepsis
4. The endothelin system in septic and endotoxin shock
5. Endothelin in septic patients: Effects on cardiovascular and renal function and its relationship to proinflammatory cytokines
6. Circulating endothelin-1 and tumor necrosis factor-alpha: Early predictors of mortality in patients with septic shock
7. Circulating adhesion molecules in disease
8. Induction of ICAM-1 by TNF-alpha, IL-1beta, and LPS in human endothelial cells after downregulation of PKC
9. INF-gamma regulates the expression of the adhesion molecule ELAM-1 and IL-6 production by human endothelial cells in vitro
10. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant sensitive mechanism in human vascular endothelial cells
11. Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans
12. Structure and function of intercellular adhesion molecule-1
13. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
14. Pathogenetic mechanisms of septic shock
15. The pathogenesis of sepsis
16. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site
17. A novel beta 1-dependent adhesion pathway on neutrophils: A mechanism invoked by dihydrocytochalasin B or endothelial transmigration
18. Rat blood neutrophils express very late antigen 4 and it mediates migration to arthritic joint and dermal inflammation
19. Transcriptional activation of vascular cell adhesion molecule-1 gene in vivo and its role in the pathophysiology of neutrophil-induced liver injury in murine endotoxin shock
20. Circulating adhesion molecules in the critically ill: A comparison between trauma and sepsis patients
21. Elevated circulating E-selectin, intercellular adhesion molecule 1, and von Willebrand factor in patients with severe infection
22. Endothelial cell activity varies in patients at risk for adult respiratory distress syndrome
23. Intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 are increased in the plasma of children with sepsis-induced multiple organ failure
24. Does age influence circulating adhesion molecules in the critically ill?
25. Soluble E-selectin levels in sepsis and critical illness: Correlation with infection and hemodynamic dysfunction
26. Increased circulating adhesion molecule concentrations in patients with the systemic inflammatory response syndrome: A prospective cohort study
27. Circulating ICAM-1 is increased in septic shock
28. Levels of soluble adhesion molecules and cytokines in patients with septic multiple organ failure
29. Cytokines and adhesion molecules in elective and accidental trauma-related ischemia/reperfusion
30. Are circulating adhesion molecules specifically changed in cardiac surgical patients?
31. Expression of adhesion molecules and cytokines after coronary artery bypass grafting during normothermic and hypothermic cardiac arrest
32. Protection against septic shock in mice with SJC13, an azaindolidine derivative that is a cell adhesion molecule inhibitor
33. Leukocyte CD18 monoclonal antibody worsens endotoxemia and cardiovascular injury in canines with septic shock
34. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
35. The roles of protein C and thrombomodulin in the regulation of blood coagulation
36. Thrombomodulin is present in human plasma and urine
37. Soluble thrombomodulin: A specific parameter of endothelial injury
38. Increased circulating thrombomodulin in children with septic shock
39. Dysfunction of endothelial protein C activation in severe meningococcal sepsis
40. Increased plasma levels of soluble thrombomodulin in patients with sepsis and organ failure
41. Plasma levels of thrombomodulin increase in cases of disseminated intravascular coagulation with organ failure
42. Thrombomodulin in intensive care patients
43. Thrombomodulin and angiotensin-converting enzyme activity during pediatric open heart operations
44. Normothermic versus hypothermic cardiopulmonary bypass: Do changes in coagulation differ?
45. Antithrombotic effects of recombinant human soluble thrombomodulin in a rat model of vascular shunt thrombosis
46. Antithrombotic effect of recombinant human soluble thrombomodulin on endotoxin-induced disseminated intravascular coagulation in rats
47. The effects of recombinant human thrombomodulin on endotoxin-induced multiple-system organ failure in rats
48. Presence of factor VIII-related antigen in blood platelets of patients with von Willebrand's disease
49. Biosynthesis of von Willebrand protein by human megakaryocytes
50. Biochemistry and genetics of von Willebrand factor
51. Endothelial cell damage in primary bilary cirrhosis: Influence of cholestasis and immunological mechanisms
52. Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome
53. Interleukin-1 or endotoxin increases the release of von Willebrand factor from human endothelial cells
54. Fibrin induces release of von Willebrand factor from endothelial cells
55. Plasma levels of the three endothelial-specific proteins von Willebrand factor, tissue factor pathway inhibitor, and thrombomodulin do not predict the development of acute respiratory distress syndrome
56. Increased plasma von Willebrand factor in the systemic inflammatory response syndrome is derived from generalized endothelial cell activation
57. Time course of hemostatic abnormalities in sepsis and its relation to outcome
58. Circulating endothelial cells in patients with septic shock
59. Endothelial apoptosis is induced by serum of patients after cardiopulmonary bypass
60. Changes of the hemostatic network in critically ill patients - Is there a difference between sepsis, trauma, and neurosurgery patients?
61. The protein C pathway: New insights
62. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C
63. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium
64. Alteration of fibrin network by activated protein C
65. The role of neutrophil elastase in human pulmonary artery endothelial cell injury
66. Endothelial protein C receptor
67. Low levels of protein C are associated with poor outcome in severe sepsis
68. Septic shock, multiple organ failure, and disseminated intravascular coagulation
69. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases
70. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications
71. Acquired antithrombin III deficiency: Laboratory diagnosis, incidence, clinical implications and treatment with antithrombin III concentrate
72. Heparin promotes the inactivation of antithrombin by neutrophil elastase
73. The disturbance of hemostasis in septic shock: Role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution
74. High-dose antithrombin III in severe sepsis
75. Substitution therapy with an antithrombin III concentrate in shock and DIC
76. Protein C, protein S and C4b-binding protein in severe infection and septic shock
77. Substitution of antithrombin III in shock and DIC: A randomized study
78. Antithrombin levels related to infections and outcome
79. Fibrinolysis and coagulation in patients with infectious disease and sepsis
80. Factor II related antigen and antithrombin III levels as indicators of liver failure in consumption coagulopathy
81. Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia
82. Time course and prognostic significance of hemostatic changes in sepsis: Relation to tumor necrosis factor-alpha
83. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients
84. Identification of alpha2-macroglobulin as a carrier protein for IL-6
85. Synthesis and secretion of multiple forms of beta2-interferon/B-cell differentiation factor2/hepatocyte stimulating factor by human fibroblasts and monocytes
86. Interleukin-6 triggers the association of its receptor with a possible signal transducer gp130
87. Lipopolysaccharide stimulates the tyrosine phosphorylation of mitogen-activated protein kinases p44, p42, and p41 in vascular endothelial cells in a soluble CD 14-dependent manner: Role of protein tyrosine phosphorylation in lipopolysaccharide-induced stimulation of endothelial cells
88. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation
89. Cytokines and cytokine antagonists in sepsis and critical illness
90. Antibodies to cachectin/tumor necrosis factor reduce interleukin-1beta and interleukin-6 appearance during lethal bacteremia
91. Tumor necrosis factor (cachectin) and other cytokines in septic shock: A review of the literature
92. Identification of the human 26 kDa protein, interferon beta2 (INFbeta2) as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor
93. Interleukin-6: An overview
94. The biology of interleukin-6
95. Septic shock in humans, advances in the understanding of pathogenesis, cardiovascular dysfunction and therapy
96. Serum cytokine levels in human septic shock: Relation to multiple-system organ failure and mortality
97. Increased plasma levels of interleukin-6 in sepsis
98. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES study
99. Cytokine profile and correlation to the APACHE III and MPM II scores in patient with sepsis
100. Reciprocal changes in circulating intereukin-6 and its soluble receptor during evolving sepsis in leukocytopenic patients
101. Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma
102. Plasma cytokine and endotoxin levels correlate with survival in patients with sepsis syndrome
103. Correlation of plasma cytokine elevations with mortality rate in children with sepsis
104. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study
105. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis
106. Comparison of procalcitonin, sCD14 and interleukin-6 values in septic patients
107. Outcome prediction by traditional and new markers of inflammation in patients with sepsis
108. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit
109. Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6
110. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis
111. Sepsis and serum cytokine concentrations
112. Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome
113. Customized probability models for early severe sepsis in adult intensive care patients
114. High tumor necrosis factor serum levels is associated with increased survival in patients with abdominal septic shock: A prospective study in 59 patients
115. Kinetics of circulating adhesion molecules and chemokines after mechanical trauma and burns